Icatibant is a synthetic peptide of 10 amino acids that blocks the bradykinin B2 receptor. Blocking that receptor eases the swelling of hereditary angioedema attacks. This guide covers its structure, mechanism, FDA-labeled use, pivotal trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Icatibant is a prescription bradykinin B2 receptor antagonist. Its label covers acute attacks of hereditary angioedema (HAE) in adults 18 and older. It has no boxed warning. Local site reactions were reported in almost all patients in clinical trials. Brand and generic versions are on DailyMed.
Vitrapep does not sell icatibant; this page is a reference summary of published research and regulatory information.
What is icatibant?
The Firazyr label describes icatibant as “a synthetic decapeptide with five non-proteinogenic amino acids” (Firazyr label, 2025). A decapeptide is a chain of 10 amino acids. Non-proteinogenic means five of them are not among the standard amino acids that cells use to build proteins.
That 10-amino-acid chain makes icatibant a peptide in the plainest sense. The unusual building blocks are part of its design as a synthetic drug. PubChem lists the formula as C59H89N19O13S and the molecular weight as 1,304.5 g/mol (PubChem CID 6918173). Our peptide primer and guide to peptide types explain the basics.
Drugs@FDA lists the original approval of Firazyr (NDA 022150) on August 25, 2011, and names Takeda as the company (Drugs@FDA).
Icatibant: key facts
| Fact | Detail |
|---|---|
| Structure type | Synthetic decapeptide (10 amino acids, five of them non-proteinogenic) |
| Class | Bradykinin B2 receptor antagonist |
| Molecular formula | C59H89N19O13S |
| Molecular weight | 1,304.5 g/mol |
| First FDA approval | August 25, 2011 (Firazyr, NDA 022150) |
| Brand names (US) | Firazyr, Sajazir; generic labels from several makers |
How does icatibant work?
The Firazyr label explains the disease first. HAE comes from a missing or faulty C1-esterase inhibitor, a key brake on the Factor XII and kallikrein cascade. That cascade produces bradykinin. The label describes bradykinin as a vasodilator, which widens blood vessels, and links it to the localized swelling, inflammation and pain of attacks.
The label states: “Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin.” Competitive means it sits in the receptor where bradykinin would bind. With the receptor occupied, bradykinin cannot set off the swelling signal. Compare ecallantide, which works one step earlier by blocking plasma kallikrein, the enzyme that releases bradykinin.
What is icatibant approved for?
The Firazyr label lists one indication: “the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.” It covers attacks as they happen and does not list prevention.
The label lists no contraindications. It does carry a warning about attacks that affect the larynx (voice box). “Given the potential for airway obstruction during acute laryngeal HAE attacks,” the label says patients should get care at an appropriate healthcare facility immediately.
What did the key trials show?
FAST-3. This randomized, double-blind, placebo-controlled phase 3 human trial enrolled adults with acute HAE attacks (NCT00912093). Among 88 patients with skin or abdominal attacks, 43 received icatibant and 45 placebo. The primary end point was median time to at least 50% reduction in symptom severity. It was 2.0 hours with icatibant and 19.8 hours with placebo (P<0.001) (Lumry et al., 2011).
FAST-1 and FAST-2. These two double-blind, randomized trials were published together (Cicardi et al., 2010). FAST-1 compared icatibant with placebo in 56 patients. Median time to clinically significant relief was 2.5 hours versus 4.6 hours, a difference that was not significant (P=0.14). FAST-2 compared icatibant with tranexamic acid in 74 patients. Median time to relief was 2.0 hours versus 12.0 hours (P<0.001).
The mixed FAST-1 result is part of the record. The Firazyr label reports the later FAST-3 trial, with its clearer placebo gap, in the most detail.
What side effects does the label list?
The Firazyr label has no boxed warning. It states that the most common adverse reactions were local site reactions, “which occurred in almost all patients (97%) in clinical trials.” In the placebo-controlled table, these occurred in 75 of 77 icatibant patients (97%) and 25 of 75 placebo patients (33%).
Other common reactions, reported in more than 1% of patients, were fever, raised liver enzymes (transaminase increase), dizziness and rash. The only listed warning concerns laryngeal attacks, described above.
What is icatibant’s regulatory status, and how is it used in research?
Icatibant is a prescription drug in the United States. A DailyMed search returns 9 icatibant labels (DailyMed). They include Firazyr from Takeda, Sajazir from Cycle Pharmaceuticals, and generics from makers such as Fresenius Kabi, Teva, Cipla and Hikma.
The research summarized here is clinical: randomized human trials in acute HAE attacks. We found no documented role for icatibant as a laboratory reagent in the sources we checked.
Frequently asked questions about icatibant
Is icatibant a peptide?
Yes. The label calls it a synthetic decapeptide: a chain of 10 amino acids, five of them non-proteinogenic.
When was icatibant approved?
Drugs@FDA lists the original approval of Firazyr on August 25, 2011.
What receptor does icatibant block?
The bradykinin B2 receptor. The label calls it a competitive, selective antagonist with an affinity similar to bradykinin.
How is icatibant different from ecallantide?
Icatibant blocks the receptor that bradykinin acts on. Ecallantide blocks plasma kallikrein, which makes bradykinin. Icatibant’s label covers adults 18 and older; the Kalbitor label covers patients 12 and older.
Does icatibant have a boxed warning?
No. Local site reactions are the most common adverse reaction, and the label warns about laryngeal attacks.
What to know now
- Structure: synthetic decapeptide with five non-proteinogenic amino acids; 1,304.5 g/mol.
- Approval: Firazyr, August 25, 2011; generics available; prescription only.
- Mechanism: competitive, selective bradykinin B2 receptor antagonist.
- Evidence: 2.0 vs 19.8 hours to 50% symptom relief in FAST-3.
- Label: acute HAE attacks in adults 18 and older.
- Safety: no boxed warning; local site reactions in 97% of trial patients.
What we’re watching
Further revisions to the Firazyr label on DailyMed, last revised in June 2025. Related guides: ecallantide, pegcetacoplan and zilucoplan.